(Q37463898)

20 August 2017

1 reference

title

Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. (English)

1 reference

metastatic renal cell carcinoma

20 August 2017

1 reference

1 reference

Ronald M Bukowski

1

1 reference

PubMed ID

19402065

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

115

1 reference

20 August 2017

10 Suppl

1 reference

20 August 2017

2273-2281

1 reference

Heterogeneity in renal cell carcinoma and its impact no prognosis--a flow cytometric study

20 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

Global increases in kidney cancer incidence, 1973-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.24226

1 reference

7 January 2021

The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Metastatic Renal Cell Cancer and Radical Nephrectomy: Identification of Prognostic Factors and Patient Survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Metastatic renal carcinoma comprehensive prognostic system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Serum acute phase reactants and prognosis in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Impact of immune parameters on long-term survival in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Retrospective analysis of 156 cases of metastatic renal cell carcinoma: evaluation of prognostic factors and response to different treatments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Improved prognostication of renal cell carcinoma using an integrated staging system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

A comparative analysis of grading systems in renal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Value of morphometry as an independent prognostic factor in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Computerized nuclear morphometry and survival in renal cell carcinoma: comparison with other prognostic indicators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Flow cytometric analysis of nuclear DNA content of renal cell carcinoma correlated with histologic and clinical features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24226

7 January 2021

Identifiers

DOI

10.1002/CNCR.24226

1 reference

20 August 2017

1 reference

PubMed ID

19402065